NCT00181558已完成2 期
Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 44
- 试验地点
- 4
- 主要终点
- To compare the effects of Atrasentan monotherapy with combination therapy using Atrasentan and Zometa on bone specific alkaline phosphatase.
研究概览
简要总结
The main purpose of this study is to look at the effects (good or bad) that Atrasentan given alone and Atrasentan given with Zometa has on levels of bone formation and bone destruction in men with prostate cancer that has spread to the bones.
详细描述
- Patients will be randomized to either receive Atrasentan alone or Atrasentan plus Zometa.
- Patients receiving Atrasentan alone will receive this drug in pill form once daily for 12 weeks. Patients will have a physical exam, blood work, and a urine sample performed once every other week during the first four weeks of medication administration. After those two initial visits, they will return to the clinic once every 4 weeks to have the same tests repeated. A bone scan and abdominal-pelvic CT Scan will be done every 12 weeks.
- After the patient has been taking Atrasentan for 12 weeks, if the disease has not progressed, they will begin combination treatment of Atrasentan and Zometa.
- Patients receiving Atrasentan plus Zometa, receive Zometa intravenously and then immediately start Atrasentan orally once daily as long as they remain on the study. Patients will return to the clinic twice over the first 4 weeks (once every other week) to have a physical exam, blood work and urine test performed. After these two initial visits, they will return to the clinic once every 4 weeks to have the tests repeated and to receive another treatment of zometa. A bone scan and an abdominal-pelvic CT Scan will be done once every 12 weeks.
- Patients participation in this study will last as long as the disease does not progress and they are not experiencing any serious side effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed adenocarcinoma of the prostate
- •History of bilateral orchiectomy or current treatment with a GnRH agonist or antagonist
- •Radiographically documented bone metastases
- •Disease progression according to criteria from the PSA Working Group
排除标准
- •Prior treatment with Atrasentan or Zometa within one year
- •Serum creatinine > 2.0mg/dL
- •Documented cardiovascular disability status of New York Heart Association Class 2
- •Treatment with chemotherapy, radiation, steroids, estrogens, or PC-SPES within 6 weeks
- •Treatment with bisphosphonates or radiopharmaceuticals within 12 weeks
- •History of Paget's disease, hyperthyroidism, hyperparathyroidism, Cushing's syndrome, hyperprolactinemia or other disorder associated with metabolic bone disease.
结局指标
主要结局
To compare the effects of Atrasentan monotherapy with combination therapy using Atrasentan and Zometa on bone specific alkaline phosphatase.
次要结局
- To evaluate the effects of Atrasentan monotherapy and combination therapy with Atrasentan and Zometa on PSA doubling time.
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate CancerProstatic NeoplasmsNCT00036556Abbott941
已完成
3 期
The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner SyndromeTurner SyndromeNCT00029159Thomas Jefferson University200
已完成
2 期
Atrasentan Spermatogenesis and Testicular FunctionNephropathyDiabetesNCT02118714AbbVie20
终止
2 期
Testosterone and Alendronate in Hypogonadal MenHypogonadismOsteopeniaOsteoporosisNCT01460654Massachusetts General Hospital44
已完成
2 期
Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or PlaceboSeizure DisorderHypogonadismErectile DysfunctionNCT00179517Beth Israel Deaconess Medical Center40